公开(公告)号：US20240309002A1

公开(公告)日：2024-09-19

申请号：US18665923

申请日：2024-05-16

Applicant: Shionogi & Co., Ltd.

Inventor： Kouhei NODU ,  Yusuke Tateno ,  Kengo Masuda ,  Yuji Nishiura ,  Yoshikazu Sasaki ,  Yu Hinata

IPC: C07D471/20 ,  A61K31/438 ,  A61K31/444 ,  C07D471/10 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

CPC classification number: C07D471/20 ,  A61K31/438 ,  A61K31/444 ,  C07D471/10 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

Abstract: The present invention provides the compound represented by the following formula (I):






wherein a moiety represented by formula:








or the like;

y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula:





L1 is a single bond or the like; L2 is —C(═O)— or the like; La is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.

公开(公告)号：US12064438B2

公开(公告)日：2024-08-20

申请号：US16764067

申请日：2018-11-15

Applicant: Shionogi & Co., Ltd.

Inventor： Naomi Hayashi ,  Masato Gomi ,  Shohei Aikawa

IPC: A61K31/5383 ,  A61K9/20 ,  A61K9/28 ,  A61P31/16

CPC classification number: A61K31/5383 ,  A61K9/2054 ,  A61K9/2813 ,  A61K9/2846 ,  A61K9/2866 ,  A61P31/16

Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.

公开(公告)号：US20240217966A1

公开(公告)日：2024-07-04

申请号：US18281848

申请日：2022-03-23

Applicant: Shionogi & Co., Ltd.

Inventor： Misato KITAMURA FUJIWARA ,  Shomitsu MAENO ,  Yuji NISHIURA

IPC: C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  C07D405/14

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  C07D405/14

Abstract: The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt.
Provided is a compound represented by formula (I):






wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by:










is a ring represented by:










 and the like
wherein
R10 is each independently halogen or the like,
s is 0 or the like,
R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, or
a pharmaceutically acceptable salt thereof.

公开(公告)号：US12024519B2

公开(公告)日：2024-07-02

申请号：US17525010

申请日：2021-11-12

Applicant: Shionogi & Co., Ltd.

Inventor： Kouhei Nodu ,  Yusuke Tateno ,  Kengo Masuda ,  Yuji Nishiura ,  Yoshikazu Sasaki

IPC: A61K31/438 ,  A61K31/444 ,  C07D471/10 ,  C07D471/20 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

CPC classification number: C07D471/20 ,  A61K31/438 ,  A61K31/444 ,  C07D471/10 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

Abstract: The present invention provides the compound represented by the following formula (I):




wherein a moiety represented by formula:





is





or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

公开(公告)号：US20240180954A1

公开(公告)日：2024-06-06

申请号：US18264190

申请日：2022-02-02

Applicant: SHIONOGI & CO., LTD.

Inventor： Akira KUGIMIYA ,  Jun NAKAMURA ,  Norikazu KURODA ,  Tetsuya TANINO ,  Atsushi HAYATA ,  Ippei MORITA ,  Shun KITAHATA

IPC: A61K31/713 ,  A61K31/7105 ,  A61K47/16 ,  C07C229/24 ,  C07D211/46

CPC classification number: A61K31/713 ,  A61K31/7105 ,  A61K47/16 ,  C07C229/24 ,  C07D211/46

Abstract: The present invention provides novel cationic lipids having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by Formula (I) or a pharmacologically acceptable salt thereof. In the Formula (I), R1 is a substituted or unsubstituted formula: (CH2)a—L1—(CH2)b—CH3; R2 is a substituted or unsubstituted C5-C20 alkyl group or a substituted or unsubstituted formula: —(CH2)c—L2—(CH2)a—CH3; L1 and L2 are each independently —C(═O)O—, —OC(═O)—, or —OC(═O)O—; a, b, c, and d are each independently an integer of at least 1, and the total of a and b and the total of c and d are each an integer of 5 to 25; R3 to R7 are each independently a hydrogen atom, a substituted or unsubstituted C1-C6 alkyl group, or the like; R8, R9, and R10 are each a hydrogen atom; the constituent atoms in the Formula (I) may form a ring; Z is —OC(═O)—, —C(═O)O—, —OC(═O)O—, or the like; and X is O or S.

公开(公告)号：US20240148741A1

公开(公告)日：2024-05-09

申请号：US18277445

申请日：2022-11-22

Applicant: Shionogi & Co., Ltd.

Inventor： Masato GOMI ,  Kensuke HORIUCHI ,  Masayuki MORIMOTO ,  Keisuke TAKAGAKI

IPC: A61K31/53 ,  A61K9/20 ,  A61K47/26 ,  A61P31/14

CPC classification number: A61K31/53 ,  A61K9/2054 ,  A61K47/26 ,  A61P31/14

Abstract: The present invention provides a formulation for oral administration, comprising a triazine derivative having virus proliferation inhibitory action.

公开(公告)号：US20230212154A1

公开(公告)日：2023-07-06

申请号：US17733366

申请日：2022-04-29

Applicant: Shionogi & Co., Ltd. ,  NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

Inventor： Yuki TACHIBANA ,  Shota UEHARA ,  Yuto UNOH ,  Kenji NAKAHARA ,  Yoshiyuki TAODA ,  Yukiko YAMATSU ,  Shigeru ANDO ,  Michihito SASAKI

IPC: C07D403/14 ,  A61K47/54 ,  A61P31/14

CPC classification number: C07D403/14 ,  A61K47/542 ,  A61P31/14

Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.
A compound represented by Formula:





, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230158036A1

公开(公告)日：2023-05-25

申请号：US17916253

申请日：2021-04-02

Applicant: Shionogi & Co., Ltd.

Inventor： Takayuki KAMEYAMA ,  Hiroyuki KAI

IPC: A61K31/53 ,  A61P13/10 ,  A61P25/02 ,  A61P25/04

CPC classification number: A61K31/53 ,  A61P13/10 ,  A61P25/02 ,  A61P25/04

Abstract: The present invention relates to a pharmaceutical composition comprising a P2X3 and/or P2X2/3 receptor antagonist for the treatment of neuropathic pain, nociceptive pain or visceral pain, as well as interstitial cystitis and/or bladder pain syndrome.
It is a pharmaceutical composition for treating and/or preventing neuropathic pain, nociceptive pain, or visceral pain, as well as interstitial cystitis and/or bladder pain syndrome, comprising a compound represented by Formula (I):




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11638717B2

公开(公告)日：2023-05-02

申请号：US16497323

申请日：2018-03-28

Applicant: SHIONOGI & CO., LTD.

Inventor： Akira Kugimiya ,  Mitsuaki Sekiguchi ,  Norikazu Kuroda ,  Jun Nakamura ,  Tetsuya Tanino ,  Yasunori Mitsuoka ,  Takeshi Kasuya ,  Yasuharu Kato

IPC: A61K31/7088 ,  A61K47/50 ,  C12N15/113

Abstract: The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines.
Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.

公开(公告)号：US20230119479A1

公开(公告)日：2023-04-20

申请号：US17757143

申请日：2020-12-09

Applicant: SHIONOGI & CO., LTD.

Inventor： Kosuke ANAN ,  Hidekuni YAMAKAWA ,  Ken YOSHIHARA ,  Kenji NAKAHARA ,  Kenji TAKAYA ,  Keisuke MIZOTE ,  Hiroyuki KAI

IPC: C07D401/14 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D403/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D401/12 ,  C07D403/12 ,  C07D498/04 ,  C07D491/107

Abstract: A novel compound having HDAC2 inhibitory activity is provided. A compound represented by Formula (I): wherein the group represented by Formula: is a group represented by Formula: or the like, wherein R3 is each independently amino or the like, and n is an integer of 0 to 4, X1 is N or the like, X2 is N or the like, R4 and R5 are each independently a hydrogen atom or the like, R1 is substituted with Substituent group C or unsubstituted non-aromatic carbocyclyl or the like, Substituent group C is halogen or the like, and R2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof.